MA40910A - Poudres de rapamycine pour administration pulmonaire - Google Patents

Poudres de rapamycine pour administration pulmonaire

Info

Publication number
MA40910A
MA40910A MA040910A MA40910A MA40910A MA 40910 A MA40910 A MA 40910A MA 040910 A MA040910 A MA 040910A MA 40910 A MA40910 A MA 40910A MA 40910 A MA40910 A MA 40910A
Authority
MA
Morocco
Prior art keywords
rapamycin
powders
pulmonary administration
pulmonary
administration
Prior art date
Application number
MA040910A
Other languages
English (en)
Inventor
Abhijit Kamerkar
Michael M Lipp
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of MA40910A publication Critical patent/MA40910A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA040910A 2014-11-07 2015-11-05 Poudres de rapamycine pour administration pulmonaire MA40910A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462076651P 2014-11-07 2014-11-07

Publications (1)

Publication Number Publication Date
MA40910A true MA40910A (fr) 2017-09-12

Family

ID=54697649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040910A MA40910A (fr) 2014-11-07 2015-11-05 Poudres de rapamycine pour administration pulmonaire

Country Status (8)

Country Link
US (1) US9387169B2 (fr)
EP (1) EP3215121B1 (fr)
JP (2) JP2017533212A (fr)
AU (2) AU2015342919B2 (fr)
CA (1) CA2966637C (fr)
ES (1) ES3022184T3 (fr)
MA (1) MA40910A (fr)
WO (1) WO2016073836A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
PL3125875T3 (pl) 2014-04-04 2023-11-20 AI Therapeutics, Inc. Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
US20200230115A1 (en) * 2017-07-24 2020-07-23 University Of Cincinnati Methods of treating influenza-associated viral pneumonia
WO2019084293A1 (fr) 2017-10-25 2019-05-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions et procédés pour administrer des agents pharmaceutiques

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
CA2277801C (fr) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20040039047A1 (en) 1998-08-11 2004-02-26 Mark Zamoyski Compositions and methods for treating lung cancers
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
CA2413692C (fr) * 2000-06-27 2011-10-18 Vectura Limited Procede permettant de produire des particules destinees a etre utilisees dans une composition pharmaceutique
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AU2002230993B2 (en) 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
CA2456746A1 (fr) 2001-08-20 2003-02-27 Transave, Inc. Procede destine a traiter des cancers du poumon
EP1424898A4 (fr) 2001-08-20 2008-04-02 Transave Inc Traitement du cancer par inhalation de formulations stables contenant platine
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
WO2003043585A2 (fr) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions particulaires ameliorees destinees a etre administrees par voie pulmonaire
DK1485154T3 (da) 2002-03-20 2008-08-04 Alkermes Inc Pulverinhalationsindretning
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
ES2389156T3 (es) 2002-03-20 2012-10-23 Civitas Therapeutics, Inc. Administración pulmonar de levodopa
AU2003230689B2 (en) * 2002-03-20 2006-06-29 Alkermes, Inc. Inhalable sustained therapeutic formulations
US7754242B2 (en) 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
CA2486622A1 (fr) 2002-05-20 2003-12-04 Research Development Foundation Medicament de type aerosol pour l'inhibition de metastases pulmonaires
EP1531794B1 (fr) 2002-06-28 2017-05-10 Civitas Therapeutics, Inc. Épinéphrine pouvant être inhalée
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
WO2004112702A2 (fr) 2003-06-13 2004-12-29 Advanced Inhalation Research, Inc. Poudres pharmaceutiques faiblement dosees inhalables
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
BRPI0516170A (pt) 2004-09-29 2008-08-26 Cordis Corp formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina
BRPI0608573A2 (pt) 2005-03-08 2017-07-25 Lifecycle Pharma As Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.
WO2006101972A2 (fr) 2005-03-17 2006-09-28 Elan Pharma International Limited Compositions injectables de composes nanoparticulaires immunosuppresseurs
AU2006331874A1 (en) 2005-12-20 2007-07-05 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
TR201807065T4 (tr) 2006-02-02 2018-06-21 Novartis Ag Tüberöz sklerozis tedavisi.
RU2010104916A (ru) 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US20080063722A1 (en) 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
EP2066321A2 (fr) 2006-11-20 2009-06-10 Lutonix, Inc. Traitement de l'asthme et de la bronchopneumopathie chronique obstructive à l'aide de médicaments antiprolifératifs et anti-inflammatoires
EP1952807A1 (fr) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Formulation de Sirolimus
EP3326630A3 (fr) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Procédés et compositions permettant de traiter l'hypertension pulmonaire
US8496002B2 (en) 2007-06-12 2013-07-30 Civitas Therapeutics, Inc. Powder inhaler devices
WO2009026434A1 (fr) 2007-08-21 2009-02-26 Alkermes, Inc. Formulations pharmaceutiques pulmonaires
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US20120076838A1 (en) * 2009-05-27 2012-03-29 Samyang Biopharmaceuticals Corporation Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same
US9248110B2 (en) 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
US20110318277A1 (en) 2010-06-25 2011-12-29 APT Pharmaceuticals, Inc. University of Maryland, Baltimore Tacrolimus compositions for aerosol administration
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
RU2016136348A (ru) * 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
PL3125875T3 (pl) * 2014-04-04 2023-11-20 AI Therapeutics, Inc. Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem

Also Published As

Publication number Publication date
NZ731431A (en) 2024-07-05
US9387169B2 (en) 2016-07-12
AU2015342919A1 (en) 2017-05-18
EP3215121A1 (fr) 2017-09-13
AU2020250195B2 (en) 2022-06-02
US20160128936A1 (en) 2016-05-12
JP7277490B2 (ja) 2023-05-19
ES3022184T3 (en) 2025-05-28
WO2016073836A1 (fr) 2016-05-12
JP2017533212A (ja) 2017-11-09
AU2015342919B2 (en) 2020-07-23
AU2020250195A1 (en) 2020-11-05
CA2966637A1 (fr) 2016-05-12
CA2966637C (fr) 2024-02-13
EP3215121B1 (fr) 2025-02-26
JP2021054870A (ja) 2021-04-08
EP3215121C0 (fr) 2025-02-26

Similar Documents

Publication Publication Date Title
SG11201706123XA (en) Pharmaceutical compositions comprising meloxicam
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
GB201419257D0 (en) Pharmaceutical compositions
GB201618482D0 (en) Pharmaceutical compositions
GB201409471D0 (en) Pharmaceutical composition
IL249553A0 (en) Pharmaceutical preparations
GB201409488D0 (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
GB201521462D0 (en) Pharmaceutical composition
SG11201702379TA (en) Long acting pharmaceutical compositions
MA40910A (fr) Poudres de rapamycine pour administration pulmonaire
SG11201705543VA (en) Sulfonamide pharmaceutical composition
ZA201508726B (en) Pharmaceutical composition
ZA201502073B (en) Pharmaceutical composition
IL255510A (en) Pharmaceutical compositions
IL250817A0 (en) pharmaceutical preparations
GB201515310D0 (en) Pharmaceutical composition
PL3389638T3 (pl) Kompozycja farmaceutyczna zawierająca pimobendan
GB201520862D0 (en) Pharmaceutical composition
SI3089740T1 (sl) Farmacevtski sestavek
SG11201608123VA (en) Pharmaceutical composition for external use
SG10201504332VA (en) Pharmaceutical Composition
PL3160263T3 (pl) Kompozycje do zapobiegania zakażeniom
SG11201608124XA (en) Pharmaceutical composition for external use